Hypoxic microenvironments contribute to the tumorigenesis of numerous cancers by regulating the expression of a subset of miRNAs called "hypoxiamiRs." However, the function and mechanism of these deregulated miRNAs in hypoxic microenvironments within pancreatic cancers remain undefined. This study demonstrates that miR-548an is significantly downregulated in pancreatic cancer tissues and correlates with increased tumor size, advanced TNM stage, distant metastasis, and poor prognosis. Moreover, the overexpression of miR548an significantly inhibited the proliferation and invasion of pancreatic cancer cells in vitro and in vivo. We further revealed that hypoxia-induced factor-1a (HIF-1a) induces the downregulation of miR-548an in pancreatic cancer cells during hypoxia. Our co-IP and ChIP assays revealed that HIF-1a and histone deacetylase 1 (HDAC1) form a complex and bind to the hypoxia response elements (HRE) on the miR-548an promoter. In addition, inhibition of HDAC1 with trichostatin A antagonizes the suppression of miR-548 by hypoxia. Our dual luciferase assay validated that miR-548an directly binds to the 3 0 untranslated region of vimentin mRNA. The downregulation of vimentin suppresses the proliferation and invasion of pancreatic cancer cells in vitro and in vivo. In addition, vimentin was inversely correlated with miR-548an expression in pancreatic cancer samples. In conclusion, our findings suggest that the HIF-1a-HDAC1 complex transcriptionally inhibits miR-548an expression during hypoxia, resulting in the upregulation of vimentin that facilitates the pancreatic tumorigenesis. Mol Cancer Ther; 15(9);
Introduction
Pancreatic cancer is an aggressive malignancy with a 5-year survival rate of less than 5% and a median survival time of approximately 6 months (1-3). It ranks as the fourth leading cause of tumor-associated death in the United States (4) . Because of the invasive nature of pancreatic cancer, most patients are unresectable at diagnosis, and death generally results from metastasis, even during aggressive treatment (5) . Therefore, there is an urgent need to enhance our understanding of the mechanisms underlying the aggressive biology of pancreatic cancer.
miRNAs are small (20-23 nucleotides), endogenous, noncoding RNA molecules, which lead to RNA degradation or translation inhibition by imperfectly binding to complementary sequences within the 3 0 -untranslated region (3 0 UTR) of their target mRNAs (6, 7) . Growing evidence suggests that miRNAs are differentially expressed in human cancers and are extensively involved in tumorigenesis (8) . We have previously demonstrated that the deregulated miRNAs, such as miR-148b (9) and miR-141 (10) , are extensively involved in progression and metastasis of pancreatic cancer. The miR-548 family of miRNAs, such as miR-548a, miR-548d, and miR-548e, which are downregulated in cervical and lung cancers, act as tumor suppressors by targeting ErbB2, Cyclin D1, and DNMT3B (11) . miR-548d is downregulated in pancreatic cancer and also acts as a tumor suppressor by promoting apoptosis, cell-cycle arrest, and chemosensitivity (12) . In this study, we discovered that miR-548an, another member of the miR-548 family, is significantly downregulated in pancreatic cancer, suggesting potential functions for miR-548an in pancreatic tumorigenesis.
Recent studies have established a link between a specific group of miRNAs and hypoxia, a key feature of neoplastic microenvironments (13, 14) . HIF-1a is a predominant transcription factor that is induced by hypoxia (15) . It can recognize and bind to the hypoxia response elements (HRE) within the promoter of target genes to regulate its transcription (16) . HIF-1a transcriptionally promotes miR-424 expression in melanoma, glioblastoma, and colon cancer, decreasing chemosensitivity by targeting PDCD4 protein (17) . In contrast, miR-199a-3p is downregulated during hypoxia, which inhibits the proliferation, adhesion, and invasiveness of ovarian cancer cell by suppressing c-Met expression (18) . Because gene sequencing analysis has demonstrated that the promoter sequence of miR-548an contains two potential HREs, we further investigated whether the downregulation of miR-548an during hypoxia is attributed to HIF-1a.
We applied the online software TargetScan and miRDB to predict potential targets of miR-548an. Our results revealed that vimentin was a potential target of miR-548an. Vimentin is upregulated in various tumors and elicits pivotal cytoskeletal functions in metastatic cancer cells and motile mesenchymal cells (19, 20) . In pancreatic cancer, vimentin is overexpressed and associated with positive peritoneal-washing cytology, portal vein invasion, lymph node metastasis, and might serve as a crucial prognostic indicator for poor survival and insensitivity to adjuvant therapy (21) . This study further evaluated whether miR-548an affects the tumorigenesis of pancreatic cancer by directly targeting vimentin.
Materials and Methods

Cell culture and reagents
The human pancreatic cancer cell lines PANC-1 and BxPC-3 cells were purchased from the ATCC in 2014 and authenticated for genotype by DNA fingerprinting. These cell lines were passaged for less than 6 months after thawing, and no subsequent reauthentication was performed. PANC-1 and BxPC-3 cells were cultivated in RPMI1640 supplemented with 10% FBS, 1% penicillin-streptomycin and incubated with 5% CO 2 at 37 C. Hypoxia treatment was composed of 1% O 2 , 5% CO 2 , and 94% N 2 at 37 C. CoCl 2 was purchased from Sigma-Aldrich and used as a final concentration of 100 mmol/L. Trichostatin A (TSA) was purchased from Solarbio and was used at a final concentration of 10 mmol/L.
Clinical samples
Tissue samples were obtained from patients undergoing surgery in the Union Hospital (Wuhan, China). Procedures performed on those patients included pancreatectomy or palliative surgery, including I 125 seed implantation as well as choledochojejunostomy and gastroenterostomy depending on the National Comprehensive Cancer Network (NCCN) guideline for pancreatic cancer. The tissues of the palliative surgery patients were obtained by biopsy. The original histopathologic reports were obtained from each case, and the diagnosis of pancreatic cancer was confirmed. Part of the excised tissue was embedded in paraffin, and part of the sample was snap-frozen at À80 C. All of the clinical samples were collected with written informed consent of the patients, and the study was approved by the Ethics Committee at the Academic Medical Center of Huazhong University of Science and Technology.
Transfection miR-548an mimics, mimics negative control, vimentin siRNA, HIF-1a siRNA and siRNA negative controls were provided by RiboBio (Guangzhou, China) and transfected with a final concentration of 50 nmol/L. miR-548an inhibitor and an inhibitor negative control (Ribobio) were transfected with a final concentration of 100 nmol/L. HIF-1a overexpression (pcDNA-HIF-1a) and empty (pcDNA-3.1) vectors were purchased from GeneChem and transfected with 1.6 mg in 12-well plates. Sequences for miR-548an and vimentin siRNAs were cloned into lentiviral vectors; empty lentiviral vectors were used as negative controls. Table S1 .
Chromatin immunoprecipitation
ChIP analysis was performed using an EpiQuik ChIP Kit (Epigentek Group Inc.). Cells were crosslinked with formaldehyde and sonicated to an average size of 300 to 500 bp. Lysates were added to each microwell, each of which was immobilized with anti-HIF-1a or anti-RNA polymerase II antibodies (Epigentek) or normal mouse IgG. Crosslinked DNA was released from the antibody-captured protein-DNA complex, and purified using specifically designed Fast-Spin Columns. Eluted DNA was detected by RT-PCR and qRT-PCR. Experiments were repeated independently three times.
Western blot and coimmunoprecipitation analysis
Total protein was extracted from cancer cells using a lysis buffer containing proteinase inhibitors. Proteins were denatured, separated in 10% polyacrylamide gels, and transferred to polyvinylidene difluoride membranes (Millipore) for probing with the following antibodies: anti-HIF-1a (1:200, Abcam), antivimentin, anti-N-cadherin, anti-GAPDH (1:1,000; Cell Signaling Technology), HDAC1 (1:1,000; Immunoway). For detection, anti-rabbit or anti-mouse secondary antibodies conjugated to horseradish peroxidase (1:3,000; Cell Signaling Technology) were used. Band signals were visualized by ECL (Pierce) and exposure to a Kodak X-OMAT film (Sigma-Aldrich); band densities were quantified using Bio-Rad Quantity One software.
For coimmunoprecipitation (co-IP) assays, whole-cell lysates were incubated with primary antibodies at 4 C followed by incubation with ProteinA/G PLUS-Agarose (Santa Cruz Biotechnology). Agarose was collected and washed with lysis buffer. Equal volumes of each sample were analyzed by Western blot analysis.
IHC
IHC was carried out as described previously (10) . Staining of vimentin was performed on embedded tissue sections by incubation with a primary anti-vimentin antibody (1:1,000; Cell Signaling Technology) and a horseradish peroxidase-conjugated secondary antibody (1:100, Boster). The immunohistochemical staining results were evaluated by two blinded observers with the patients.
Cell proliferation assay and cell viability assay
Cell proliferation was quantitated by MTT assay. Cells were seeded into 96-well plates at a density of 2,000 cells per well and incubated at 37 C for 1 to 5 days. Twenty microliters of MTT solution (5 mg/mL) was added to each well, and the media were replaced with 150 mL DMSO after incubation for 4 hours. A microplate reader was used to detect the resulting absorbances at 570 nm. Cell viability was measured by MTT assay after cells were seeded into 96-well plates as a density of 2,000 cells per well and incubated at 37 C for 2 days. All experiments repeated independently three times; there were 5 samples per group.
Invasion and wound healing assay
Transwell migration chambers (Corning-Costar; pore size 8 mm) coated with Matrigel (Sigma) were used to assess cell invasion ability. Cells resuspended with FBS-free medium were added to the top chamber, and the bottom chamber was filled with 30% FBS as chemotaxin. The cells were cultivated at 37 C for 48 hours; the cells that failed to invade were wiped from the top of the membranes. Invasive cells on the bottom of membrane were fixed and stained. The numbers of invasive cells from five random areas of the membrane were counted with light microscopy.
For the wound-healing assay, cells were seeded into 12-well plates and allowed to grow to 90% confluence. The cell monolayers were scratched by micropipette tip and cultured in serumfree medium. Microphotographs were acquired at 0 and 48 hours. All experiments were repeated independently three times.
Luciferase assay
BxPC-3 cells were seeded into 96-well plates. One hundred nanograms of pMIR-REPORT luciferase vector containing vimentin mRNA 3 0 UTR or a mutated form was cotransfected with miR548an mimics, the mimics negative control, miR-548an inhibitor or the inhibitor negative control. After 48-hour incubation, luciferase activity was measured using a Dual-Luciferase Reporter Assay System (Promega). Firefly luciferase activity was normalized to the corresponding Renilla luciferase activity.
To investigate whether miR-548an is transcriptionally regulated by HIF-1a, pGL3-based construct containing the miR-548an promoter (a 2-kb sequence upstream of pre-miR-548an) were cotransfected with HIF-1a siRNA and a negative control, or treated with and without TSA. Cells were cultured with or without CoCl 2 . After a 48-hour incubation period, luciferase activity was measured using the Dual-Luciferase Reporter Assay System. All experiments were repeated independently three times; there were 5 samples per group.
Xenograft assay
A xenograft model was established to assess tumor formation. BxPC-3 cells transfected with lentiviral vectors (LV-miR-548an, LV-siVIM and LV-NC) were subcutaneously injected into right flanks of 4-week-old male BALB/c nude mice (HFK Bio-Technology Co., Ltd.). There were 5 mice per group. Mice were sacrificed at 21 days later, and tumor weights were measured. Tumor volumes [0.5 Â L (length) Â W 2 (width)] were measured every 3 days. The livers of mice were excised to analyze liver metastasis, and parts of liver were embedded in paraffin. All in vivo experiments of this study were approved by the Animal Research Committee of the Academic Medical Center at Huazhong University of Science and Technology.
Statistical analysis
The data analysis was performed using SPSS 13.0 software, and the data were presented as mean values AE SD. Differences between groups were assessed using the t test. The expression of miR-548an in 48 pancreatic cancers and paired adjacent noncancerous tissues was analyzed using the paired t test. The correlation between miR548an and vimentin expression was assessed by Pearson's correlation. The relationship between miR-548an expression and clinical characteristics was analyzed by c 2 test. The Kaplan-Meier method was used to analyze the overall survival (OS) of 2 patient groups, and the log-rank test was used to investigate differences. The survival data were evaluated using a multivariate Cox regression analysis. Significant differences were defined by P < 0.05.
Results
The expression of miR-548an is downregulated in pancreatic cancer tissues
We assessed the expression of miR-548an in 48 pancreatic cancer tissues and paired adjacent noncancerous tissues by qRT-PCR. As shown in Fig. 1A , miR-548an was significantly downregulated in pancreatic cancer tissues compared with paired noncancerous tissues (3.746 AE 0.2764 vs. 4.924 AE 0.3202, P ¼ 0.0038). In all 48 patients, 32 patients exhibited reduced expression of miR-548an in pancreatic cancer tissues compared with paired adjacent noncancerous tissues. Data were available for all 48 patients to analyze the relationship between miR-548an expression and clinicopathology (Supplementary Table S2 ). Decreased expression of miR-548an significantly correlated with increased tumor size, late TNM stage, and distant metastasis. Furthermore, the OS of patients with low miR-548an expression was reduced compared with those patients with high miR-548an expression (Fig. 1B) . Multivariate Cox analysis demonstrated that miR-548an expression and distant metastasis were associated with OS and served as independent prognostic factors (Supplementary Table S3 ). Therefore, these results suggest that reduced miR-548an levels associate with poor clinical outcomes in pancreatic cancer patients.
Overexpression of miR-548an inhibits the proliferation and invasion of pancreatic cancer cells
Because miR-548an is downregulated in the pancreatic cancer tissues, we first investigated its biological role by overexpressing miR-548an. After overexpressing miR-548an using miR-548an mimics ( Fig. 2A) , cell viability was significantly inhibited in PANC-1 and BxPC-3 cells (Fig. 2B) . Moreover, we used a miR-548an-containing lentiviral vector (LV-miR-548an) to stably overexpress miR-548an (Fig. 2C ). After transfection with LV-miR-548an, the proliferation of PANC-1 and BxPC-3 cells was significantly reduced (Fig. 2D) . Notably, the overexpression of miR-548an resulted in significantly reduced migration and invasion of PANC-1 and BxPC-3 cells (Fig. 2E and F) .
To further elaborate the biological role of miR-548an in pancreatic cancer, we evaluated the effects of a miR-548an inhibitor in pancreatic cancer cells. Treatment with the MiR-548an inhibitor significantly decreased the expression of miR-548an in PANC-1 and BxPC-3 cells (Supplementary Fig. S1A ). The miR-548an inhibitor increased the viability of PANC-1 and BxPC-3 cells (Supplementary Fig. S1B ). In addition, the invasion and migration of PANC-1 and BxPC-3 cells were significantly increased after transfection with the miR-548an inhibitor ( Supplementary  Fig. S1C and S1D) .
To further validate the in vitro effects of miR-548an in pancreatic cancer cells, BxPC-3 cells transfected with LV-NC or LV-miR548an were implanted as xenografts into a nude mouse tumor model. Compared with the LV-NC group, the tumors of the LV-miR-548an group were smaller and reduced in weight (Supplementary Fig. S2A) . Moreover, the number of liver metastases in the LV-miR-548an group was significantly reduced compared with that in the LV-NC group (Supplementary Fig. S2B ). These results indicated that miR-548an might act as an inhibitor of pancreatic cancer.
miR-548an expression is transcriptionally inhibited by HIF-1a under hypoxia
Hypoxia is a hallmark of cancer, which plays vital roles in the tumorigenesis. We also found that hypoxia significantly enhanced the migration and invasion of BxPC-3 ( Supplementary Fig. S3A and S3B). Because miRNAs can be aberrantly expressed during stress conditions such as hypoxia, we further explored whether the decreased expression of miR-548an in pancreatic cancer cells is regulated by hypoxia. As shown in Fig. 3A and B, after treatment with hypoxia or CoCl 2 , the expression of HIF-1a protein was increased, whereas the expression of miR-548an was decreased. As the miR-548an gene is located within the CXorf57 gene, we also explored whether the reduction in miR-548an was attributed to the downregulation of CXorf57 in hypoxia. Interestingly, the expression of CXorf57 mRNA was not altered in cells treated with hypoxia or CoCl 2 ( Fig. 3A and B) , suggesting that the transcription of miR-548an in hypoxia is independent of its host gene CXorf57.
To further clarify whether miR-548an is regulated by HIF-1a under hypoxia, HIF-1a expression was manipulated to assess its effects on miR-548an expression. Of the 3 HIF-1a-targeting siRNAs evaluated, siRNA-3 was chosen for the further experiments, as it induced the most significant downregulation of HIF-1a ( Supplementary Fig. S4A ). Knockdown of HIF-1a upregulated miR-548an expression and impaired the CoCl 2 -induced suppression of miR-548an (Fig. 3C) . In contrast, the overexpression of HIF-1a ( Supplementary Fig. S4B ) reduced miR-548an expression (Fig. 3D) .
A recent study demonstrated that upstream DNA sequences of miRNAs might function as miRNA promoters, which are subject to transcriptional regulation (22, 23) . The two HREs contained within the upstream region of the miR-548an promoter (Fig. 3E) suggest that HIF-1a transcriptionally regulates the expression of miR-548an. ChIP assays revealed that the region at À132 to À24 bp upstream from start site of the pre-miR-548an is occupied by HIF-1a and that this binding was enhanced during hypoxia (Fig. 3F) . To further confirm whether the binding of HIF1a to the miR-548an promoter is functional, a luciferase reporter plasmid containing the miR-548an promoter was transfected into BxPC3 cells. CoCl 2 significantly decreased the luciferase activity in BxPC3 cells, whereas knockdown of HIF-1a increased luciferase activity (Fig. 3G ). In addition, further ChIP assays revealed that Pol II could bind to the miR-548an promoter and that this binding was reduced under hypoxia ( Supplementary Fig. S5A ). Taken together, these data suggest that miR-548an is transcriptionally inhibited by HIF-1a during hypoxia.
HDAC1 is involved in HIF-mediated miR-548an downregulation during hypoxia
HDAC1 can interact with HIF-1a and downregulate the expression of downstream target genes of HIF-1a (24) . Therefore, we further investigated whether miR-548an expression was suppressed by HIF-1a/HDAC1 complex. co-IP demonstrated that HIF-1a and HDAC1 can recruit each other, and this interaction is enhanced by hypoxic conditions (Fig. 4A) . Furthermore, ChIP analysis revealed that HDAC1 can bind to the same DNA sequence as HIF-1a within the miR-548an promoter, and this binding is increased in hypoxia (Fig. 4B) . HDAC1 expression was not altered after treatment with hypoxia or CoCl 2 ( Supplementary  Fig. S6A and S6B) , suggesting that the increased binding of HDAC1 with the miR-548an promoter in hypoxia is attributed to HIF-1a. Moreover, the HDAC inhibitor TSA increased the expression of miR-548an, and the suppression of miR-548an by CoCl 2 was impaired in the presence of the TSA (Fig. 4C ). In addition, TSA distinctly upregulated the luciferase activity of miR-548an promoter reporter, which was suppressed by CoCl 2 (Fig. 4D) .
In summary, these results indicate that the cooperation of HIF-1a and HDAC1 on the miR-548an promoter suppresses miR-548an transcription.
Vimentin is a direct target of miR-548an
Given that the overexpression of miR-548an exhibited a prominent inhibition on the invasion ability, we focused on potential targets known to be involved in the metastasis of pancreatic cancer. Online software (TargetScan and miRDB) predicted that vimentin and N-cadherin were possible targets of miR-548an. Overexpression of miR-548an significantly downregulated vimentin, whereas the inhibition of miR-548an upregulated the expression of vimentin in PANC-1 and BxPC-3 ( Fig. 5A and B) . However, neither the miR-548an mimics nor the miR-548an inhibitor could regulate mRNA and protein expression of N-cadherin ( Supplementary Fig. S7A and S7B ). In pancreatic Figure 2 . MiR-548an inhibits the proliferation and invasion of PANC-1 and BxPC-3 cells. A, qRT-PCR analysis showed the expression of miR-548an in PANC-1 and BxPC-3 cells transfected with miR-548an mimics (miR-548an) or mimics negative control (miR-NC). B, the viability of PANC-1 and BxPC-3 cells was assessed by MTT assay after cells were transfected with miR-548an mimics or miR-NC. C, qRT-PCR analysis showed the expression of miR-548an in PANC-1 and BxPC-3 cells transfected with a lentivirus containing miR-548an (LV-miR-548an) or an empty lentiviral vector (LV-NC). D, the proliferation of PANC-1 and BxPC-3 cells was assessed over a 5-day period by MTT assay after cells were transfected with LV-miR-548an or LV-NC. E, assessment of migration was measured by wound-healing assay after PANC-1 and BxPC-3 cells were transfected with miR-548an or miR-NC. F, assessment of invasion was measured by Transwell assay after PANC-1 and BxPC-3 cells were transfected with miR-548an or miR-NC. The histogram shows the percentage of invaded cells per field compared with miR-NC. The data represent mean values AE SD ( Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001).
cancer tissues, a significant inverse correlation was observed between vimentin and miR-548an expression (Fig. 5C ), whereas N-cadherin expression exhibited no correlation with miR-548an expression ( Supplementary Fig. S7C ). These data indicate that vimentin, but not N-cadherin, is the target of miR-548an. The online software TargetScan and miRDB predicated that miR-548an can directly bind to the 3 0 UTR of vimentin (Fig. 5D ). To further elucidate the direct relationship between miR-548an and vimentin, we cloned the 3 0 UTR sequences that contain the predicted target sequence (wild type, WT) or mutated sequences (mutant type, MUT) of vimentin mRNA 3 0 UTR into the pMIR-REPORT luciferase vector. Cotransfection of miR-548an mimics significantly decreased the firefly luciferase activity of the reporter with wild-type 3 0 UTR but not that of the mutant reporter. In contrast, the miR-548an inhibitor increased the firefly luciferase activity (Fig. 5E) . Moreover, hypoxia and CoCl 2 significantly increased the expression of vimentin in a time-dependent manner ( Supplementary Fig. S8A and S8B ).
In summary, these experimental and clinical results strongly indicate that vimentin is directly targeted and inhibited by miR-548an in pancreatic cancer.
Knockdown of vimentin phenocopies the inhibitory effect of miR-548an in pancreatic cancer cells
To further validate the role of vimentin in pancreatic cancer cells, we first detected the expression of vimentin in pancreatic cancer tissues. Expression of vimentin mRNA in pancreatic cancer tissues was significantly higher than that of paired adjacent noncancerous tissues (Fig. 6A) . Immunohistochemical analysis revealed that vimentin is strongly expressed in the cytoplasm of pancreatic cancer cells but weakly in paired adjacent noncancerous tissues (Fig. 6B) . Furthermore, we applied RNAi to knockdown the expression of vimentin. In all of the 3 vimentin-targeted siRNAs, siRNA-2 induced the most significant downregulation of vimentin and was chosen for further experiments ( Supplementary Fig. S9A and S9B ). The The expression of miR-548an of pancreatic cancer cells is regulated by HIF-1a during hypoxia. A and B, PANC-1 and BxPC-3 were treated with hypoxia (1% O 2 ) or CoCl 2 , respectively. Western blot analysis revealed protein expression levels of HIF-1a, and qRT-PCR analysis showed the CXorf57 mRNA and miR-548an expression. The curve diagram shows variation of HIF-1a, CXorf57 mRNA, and miR-548an levels in PANC-1 and BxPC-3 cultured in 1% O 2 or CoCl 2 for the indicated times. C, miR-548an expression levels in PANC-1 and BxPC-3 cells transfected with HIF-1a siRNA (siHIF-1a) or negative control (NC) and cultured with or without CoCl 2 . D, levels of miR-548an expression in PANC-1 and BxPC-3 cells transfected with HIF-1a overexpression vector (pcDNA-HIF-1a) or empty vector (pcDNA3.1). E, a schematic illustration of the proximal region of the miR-548an promoter and the region detected by ChIP assay. F, after BxPC-3 cells were cultured in hypoxia or normoxia, ChIP with anti-HIF-1a antibody was performed to verify the binding between HIF-1a and the miR-548an promoter in BxPC-3 cells. G, BxPC-3 cells, which were transfected with empty pGL3 vector (vector) or a miR-548an promoter-containing pGL3 reporter vector (miR-548an promoter), were cotransfected with siHIF-1a or NC. At 24 hours after transfection, the cells were cultured with or without CoCl 2 for 24 hours. Firefly luciferase activity was detected and normalized by Renilla luciferase activity. The data represent mean values AE SD ( Ã , P < 0.05; ÃÃ , P < 0.01). viability of PANC-1 and BxPC-3 was suppressed after the downregulation of vimentin (Fig. 6C ). After transfection with the lentiviral vector containing vimentin siRNA-2 (LV-siVIM), cell growth was inhibited in PANC-1 and BxPC-3 (Fig. 6D) .
Moreover, the downregulation of vimentin also suppressed the migration and invasion of pancreatic cancer cells ( Fig. 6E and  F) . In addition, the miR-548an inhibitor rescued the expression of vimentin and the invasiveness of the pancreatic cancer cells, Figure 5 .
Vimentin is a direct target of miR-548an. A, qRT-PCR and Western blot analysis showed vimentin mRNA and protein expression levels in PANC-1 and BxPC-3 cells transfected with miR-548an or miR-NC. B, qRT-PCR and Western blot analysis showed vimentin mRNA and protein expression in PANC-1 and BxPC-3 cells transfected with a miR-548an inhibitor (inh-548an) or inhibitor negative control (inh-NC). C, the relationship between miR-548an and vimentin expression was analyzed by Spearman's correlation in pancreatic tissue specimens. D, sequence alignment of predicted miR-548an-binding sites within the 3 0 UTR of vimentin mRNA. E, BxPC-3 cells transfected with a luciferase reporter of wild-type or a mutant 3 0 UTR of vimentin mRNA were cotransfected with miR-548an, miR-NC, inh-548an, or inh-NC. Firefly luciferase activity was detected and normalized by Renilla luciferase activity. The data represent mean values AE SD ( Ã , P < 0.05; ÃÃ , P < 0.01). Fig. S10A and S10B).
Our in vivo results showed that LV-siVIM significantly repressed the average weight and volume of the implanted tumors (Supplementary Fig. S11A) . Moreover, the number of average liver metastasis also decreased significantly in the LV-siVIM group (Supplementary Fig. S11B ).
Discussion
Increasing evidence demonstrates that aberrant miRNA expression is closely associated with tumorigenesis during hypoxia (25) . However, the function and mechanism of those deregulated miRNAs during hypoxia in pancreatic cancer has not been fully elucidated. Significantly, our study suggests a novel mechanism in which HIF-1a transcriptionally downregulates miR-548an expression in pancreatic cancer by recruiting HDAC1 to the promoter of miR-548an during hypoxia.
Certain miRNA genes reside within the introns of proteincoding genes and thus, share the promoter of the host gene (26) . However, the promoters of miRNAs are occasionally distinct from the promoters of their host gene, and therefore, transcription of miRNA can be independent of host gene transcription (27) . In this study, hypoxia and CoCl 2 do not regulate the expression of CXorf57, which is a miR-548an host gene. This result suggests that the miR-548an host gene CXorf57 does not contribute to the downregulation of miR-548an during hypoxia, and further, that miR-548an is an intronic miRNA that might have its own promoter.
The promoter of miRNAs can contain transcription factorbinding sites that are relevant to deregulation in disease (28) . HIF-1a plays an essential role in upregulating the expression of a subset of miRNAs during hypoxia (called "hypoxiamiRs"; ref. 29) . Nevertheless, some miRNAs are downregulated during hypoxia, and the mechanism of this downregulation is not fully understood (30) . Research demonstrates that hypoxia downregulates Drosha and Dicer in cancer cells, resulting in the deregulation of miRNA biogenesis and increased tumor progression (31) . The hypoxic mimetic desferrioxamine (DFX) or CoCl 2 , as well as the overexpression of HIF-1a reduces the expression of miR-503 in HepG2 cell (32) . Our findings revealed that HIF-1a suppresses the transcription of miR-548an directly by binding to its promoter.
Although several studies have demonstrated that HIF-1a transcriptionally upregulates a number of oncogenes, other studies have found that HIF-1a can recruit HDACs to transcriptionally inhibit target gene expression. HIF-1a directly restrains cyclin D1 expression by recruiting HDAC7 to the promoter of cyclin D1 (33) . Other studies found that hypoxia downregulates the expression of the tumor-suppressor RECK through the recruitment of HDAC1 and HIF-1a complex to promoter (34) . Our study demonstrates that HIF-1a, which accumulates during hypoxia, recruits more HDAC1 to the promoter of miR-548an. Furthermore, inhibition of HDAC1 by TSA relieves the suppression of miR-548an expression by HIF-1a during hypoxia. Nevertheless, the expression of HDAC1 does not increase during hypoxia. These results strongly indicate that HDAC1 is required for HIF-1a-mediated transcriptional inhibition of miR-548 expression.
In the functional experiments, we found that miR-548an overexpression significantly inhibits the proliferation and invasion of pancreatic cancer cells both in vitro and in vivo, whereas a miR548an inhibitor elicits the opposite effect. Clinical analysis revealed that downregulation of miR-548an is an independent prognostic factor and is associated with distant metastasis in pancreatic cancer patients. These data indicate that miR-548an is an inhibitor of pancreatic tumorigenesis. Bioinformatic prediction indicated that vimentin and N-cadherin, vital mesenchymal markers that participate in EMT and metastasis of tumor (35, 36) , are potential targets of miR-548an. Interestingly, we demonstrated that vimentin, but not N-cadherin, is regulated by miR-548an. Moreover, the downregulation of vimentin inhibits the proliferation and invasion of pancreatic cancer cells, which is rescued by miR-548an inhibitor. In addition, the clinical data revealed an inverse correlation between vimentin and miR-548an. These results strongly indicate that vimentin is directly targeted and inhibited miR-548an in pancreatic cancer.
In conclusion, our study demonstrates that the HIF-1a-HADC1 complex transcriptionally inhibits miR-548an expression during hypoxia, resulting in vimentin overexpression and promoting the progression of pancreatic cancer. In addition, our findings support the possibility that miR-548an represents a novel biomarker and therapeutic target for pancreatic cancer.
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